key: cord-0027193-jvt5ap57
authors: Benýšek, Jakub; Buša, Michal; Rubešová, Petra; Fanfrlík, Jindřich; Lepšík, Martin; Brynda, Jiří; Matoušková, Zuzana; Bartz, Ulrike; Horn, Martin; Gütschow, Michael; Mareš, Michael
title: Highly potent inhibitors of cathepsin K with a differently positioned cyanohydrazide warhead: structural analysis of binding mode to mature and zymogen-like enzymes
date: 2022-02-11
journal: nan
DOI: 10.1080/14756366.2021.2024527
sha: 37f276bf33494bc98a39353d749604cf36287609
doc_id: 27193
cord_uid: jvt5ap57

Cathepsin K (CatK) is a target for the treatment of osteoporosis, arthritis, and bone metastasis. Peptidomimetics with a cyanohydrazide warhead represent a new class of highly potent CatK inhibitors; however, their binding mechanism is unknown. We investigated two model cyanohydrazide inhibitors with differently positioned warheads: an azadipeptide nitrile Gü1303 and a 3-cyano-3-aza-β-amino acid Gü2602. Crystal structures of their covalent complexes were determined with mature CatK as well as a zymogen-like activation intermediate of CatK. Binding mode analysis, together with quantum chemical calculations, revealed that the extraordinary picomolar potency of Gü2602 is entropically favoured by its conformational flexibility at the nonprimed-primed subsites boundary. Furthermore, we demonstrated by live cell imaging that cyanohydrazides effectively target mature CatK in osteosarcoma cells. Cyanohydrazides also suppressed the maturation of CatK by inhibiting the autoactivation of the CatK zymogen. Our results provide structural insights for the rational design of cyanohydrazide inhibitors of CatK as potential drugs.

Cathepsin K (CatK) is one of the most investigated cysteine cathepsins, both by academia and pharmaceutical companies. It is expressed in high levels in osteoclasts, where it serves as the principal protease involved in bone remodelling. It has been validated as a therapeutic target for osteoporosis, an increasing health problem in the modern world [1] [2] [3] [4] . This disorder is caused by progressive loss of bone mass due to excessive activity of osteoclastic CatK. Several anti-remodelling inhibitors of CatK, such as odanacatib or balicatib [5] [6] [7] (Figure 1 ), have been developed for the treatment of osteoporosis but have not yet been approved. CatK has also been implicated in the pathophysiology of two common forms of arthritis, osteoarthritis and rheumatoid arthritis 8, 9 . In bone and cartilage disorders, CatK functions as a potent collagen degrading enzyme with the unique ability to cleave the triple helix of collagen molecules at multiple locations, an activity that is unparalleled among human collagenases 10, 11 . This activity is induced by glycosaminoglycans, foremost chondroitin-4-sulphate, which mediates the formation of a complex between CatK and the collagen substrate 10, 12, 13 .

Further, there is increasing evidence that CatK is a protumorigenic protease that plays an important role in processes associated with tumour growth, invasion, and metastasis of cancer cells and their interactions with the tumour microenvironment (for review see 14, 15 ). Its complex action includes direct degradation of collagen and other extracellular matrix proteins, e.g. in bone metastases, and indirect affecting of the signalling pathways [16] [17] [18] [19] . In glioma, CatK can regulate cancer stem-like cell mobilisation and proteolytically modulate levels of chemokines and growth factors 20 . Thus, clinical research is investigating CatK as a marker for diagnosis and survival prognosis in metastatic cancer and as a target for anticancer inhibitors 21, 22 .

At the protein level, CatK activity is regulated by endogenous protein inhibitors 23, 24 and by zymogen activation [24] [25] [26] . CatK is synthesised as an inactive zymogen (procathepsin) in which the N-terminal propeptide blocks the active site 27, 28 . Activation to the mature, active form occurs upon proteolytic removal of the N-terminal propeptide (also termed the "activation peptide"). This process was shown to be autocatalytic and bimolecular; it is triggered by acidic pH and also enhanced by interaction with chondroitin-4-sulfate 25, 29 . The activation pathway of CatK includes an activation intermediate with a partially processed propeptide 25 , which has not been studied in detail so far, and its spatial structure remains unknown.

Peptidomimetics with a reactive nitrile functionality have attracted particular attention as potent inhibitors of CatK and other cysteine cathepsins. The electrophilic nitrile warhead allows for covalent interaction with the catalytic cysteine nucleophile, leading to the reversible formation of a covalent thioimidate adduct. Representatives of such CatK inhibitors are dipeptide nitriles odanacatib and balicatib [5] [6] [7] (Figure 1 ). An exchange of the a-CH moiety of the P1 amino nitrile by a nitrogen atom led to azadipeptide nitriles with the cyanohydrazide warhead forming a stabilised isothiosemicarbazide adduct [30] [31] [32] . They have been introduced as a class of efficient covalent-reversible inhibitors of human cysteine cathepsins, including CatK, and their homologs from parasites and pathogens [30] [31] [32] [33] [34] . Compared to their parent carbapeptide analogs, bioactive azapeptides can possess improved potency, selectivity, and pharmacokinetics [35] [36] [37] [38] . The 3-cyano-3-azab-amino acid derivatives represent another scaffold bearing the cyanohydrazide warhead 39 . They were designed to position the warhead centrally in the peptidomimetic inhibitor molecule for extended interactions of inhibitor substructures with the nonprimed and primed binding regions of the target enzymes. These compounds were found to be exceptionally potent, in particular towards CatK 39 .

The exact binding mode of peptidomimetics with the cyanohydrazide warhead to CatK had not been characterised so far. To do this, we investigated two model cyanohydrazide inhibitors selective for CatK with high potency in the subnanomolar to picomolar range, namely the azadipeptide nitrile G€ u1303 30,31 and the 3cyano-3-aza-b-amino acid derivative G€ u2602 39 ( Figure 1 ). The crystal structures of their complexes with mature CatK and the activation intermediate of CatK were determined and functional properties in vitro and in cells were described. The present structures and inhibitor interaction data provide a footing for the rational design of next generation cyanohydrazide inhibitors of CatK as potential therapeutics.

Inhibitors G€ u1303 and G€ u2602 and the CatK activity-based probe 25 were synthesised as described previously 30,39,40 .

Human CatK (Uniprot accession number P43235) was expressed in the X-33 strain of the methylotrophic yeast Pichia pastoris (Thermo Fisher). A gene coding for the zymogen form of CatK was purchased from GenScript and recloned into expression plasmid pPICZaA (Thermo Fisher) using XhoI and NotI restriction sites. Transformation of P. pastoris cells and protein expression were carried out as described previously 41, 42 . The yeast medium containing the recombinant CatK zymogen was centrifuged (2,500 g for 10 min), and the supernatant was lyophilised and dissolved in 20 mM MES pH 6.0 (to 10% of the original volume). The protein solution was then desalted over a Sephadex G-25 column equilibrated with the same buffer. The CatK zymogen was purified using chromatography on Mono S (HR 5/5 column) equilibrated with 50 mM sodium acetate pH 5.5, and eluted by a linear gradient of 2 M NaCl. The purified protein was concentrated to 2 mg/ml using an Amicon Ultracel-10k centrifugal filter device (Millipore).

The purified CatK zymogen (75 mM) was activated by incubation in 0.1 M sodium acetate pH 4.0 containing 2.5 mM DTT, 1 mM EDTA, and 0.3 M NaCl under an argon atmosphere at room temperature. The zymogen-like activation intermediate iCatK was obtained after 30 min of incubation, and fully activated mature enzyme mCatK after 75 min. Activation was terminated by the addition of 6-fold molar excess of the inhibitor G€ u1303 or G€ u2602, followed by incubation under argon atmosphere for 3 h at room temperature. The activation and inhibition were monitored with a kinetic activity assay using the fluorogenic substrate Cbz-Gly-Pro-Arg-AMC (Cbz, benzyloxycarbonyl; AMC, 7-amino-4-methylcoumarin) and Laemmli-SDS-PAGE. The processing sites were identified by N-terminal protein sequencing after electroblotting of Laemmli-SDS-PAGE gels to a PVDF membrane using a Procise 494 cLC protein sequencer (Applied Biosystems) and by peptide mapping using mass spectrometry (LC-MS/MS) on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific) coupled to a UHPLC system. The LC-MS/MS data were processed with Bioworks software (Thermo). The complexes were buffer-exchanged into 20 mM sodium acetate pH 5.5 containing 2.5 mM DTT and 0.25 M NaCl, and concentrated to 3.5 mg/ml for mCatK and 5 mg/ml for iCatK using an Amicon Ultracel-10k centrifugal filter device; the inhibitors were maintained during buffer exchange and concentration in a 6-fold molar excess to mCatK/iCatK in the mixture.

The CatK zymogen (2.8 mM) was incubated at room temperature in the presence or absence of the inhibitor (10 mM G€ u1303 or G€ u2602) in 150 mL of 0.1 M sodium acetate pH 4.0 containing 2.5 mM DTT and 0.3 M NaCl for 0, 30 and 240 min. The reaction was terminated by the addition of E-64 (10 mM final concentration), followed by acetone precipitation; the reaction mixture was separated by Laemmli-SDS-PAGE. / imidazole pH 6.5 for mCatK-G€ u2602 complex. Crystals were flashcooled by plunging them into liquid nitrogen, and diffraction data from the crystals of mCatK complexes were collected at 100 K on a MicroMax-007 HF Microfocus rotating anode X-ray generator equipped with a PILATUS 300 K detector (Rigaku). Data from the crystals of iCatK complexes were collected at 100 K on an MX 14.1 beamline operated by Helmholtz-Zentrum Berlin at the BESSY II electron storage ring in Berlin-Adlershof, Germany 43 . All diffraction data was processed using the XDS suite of programs 44 . Crystal parameters, data collection statistics, and final refinement statistics are in Table S1 .

The structures of the mCatK-G€ u1303/G€ u2602 complexes and the main domain of iCatK in complex with G€ u2602 were solved by molecular replacement with the program MolRep 45 from the CCP4 program suite 46 using the structure of human cathepsin K (PDB code: 7NXM) 40 as a search model. The propeptide domain structure in iCatK-G€ u2602 was built using the de novo model building program Buccaneer 47 . The structure of the iCatK-G€ u1303 complex was solved by molecular replacement using the structure of iCatK-G€ u2602 as a search model. Model refinement was carried out using the program REFMAC 5.5, interspersed with manual adjustments using Coot. The geometric restraints for ligands were constructed by the program AceDRG 48 . The quality of the final models was validated with MolProbity 49 . The final refinement statistics are given in Table S1 . Atomic coordinates and structure factors have been deposited in the Protein Data Bank with the accession codes: 7QBL, 7QBN, 7QBM, and 7QBO for mCatK-G€ u2602, mCatK-G€ u1303, iCatK-G€ u2602, and iCatK-G€ u1303, respectively. Inhibitor interactions were analysed using the programs CONTACT 46 and PLIP 50 . The distance cut-offs were set to 3.3 Å for hydrogen bonds and 4.2 Å for contacts. The nonpolar interactions represent contacts between two hydrophobic atoms defined as carbon atoms having carbon or hydrogen atoms as neighbours. All figures showing structural representations were prepared with the PyMOL Molecular Graphics System, version 1.40 (Schr€ odinger, LLC).

The X-ray structure of the mCatK-G€ u2602 complex was used for molecular modelling. Hydrogen atoms were added to the protein by the Reduce and Leap programs in AMBER 14 51 . The Asp, Glu, Lys, Arg, and His residues were charged, with the exception of Asp82 and His162. Hydrogen atoms of the inhibitor were added manually using the PyMOL. The ff14SB force field 51 was used for the protein, while the GAFF force field 51 and RESP charges at HF/ 6-31G Ã level were used for the ligand. The molecular dynamics/ quenching (MD/Q) technique was used to search for possible conformations of G€ u2602 in the complex. The simulations were performed using AMBER 14. During the simulations, the N-benzyl-N-methylformamide segment of the inhibitor was relaxed; specifically, the C, O, and N heavy atoms in this segment and all H atoms of the inhibitor were relaxed while the rest of the system was frozen. The structures were collected every 1 ps in two independent runs with two orientations of the relaxed inhibitor segment (i.e. the heavy atoms as above). The simulations were 10 ps long at 600 K using 1 fs time step and a Berendsen thermostat. All the obtained structures were optimised (i.e. residues within 6 Å of the inhibitor were relaxed) by using the corrected semiempirical quantum mechanical (SQM) PM6-D3H4 method 52,53 . The environment was described by the COSMO implicit solvent model 54, 55 . The SQM calculations were done by Cuby4 56 and MOPAC2016 57 . Residues further than 6 Å from the inhibitor were frozen during the optimisation.

Enzymatic activity of mCatK was measured using a kinetic continuous assay with the fluorogenic substrate Cbz-Gly-Pro-Arg-AMC (Bachem). The assay was performed in a 96-well microplate format in a total assay volume of 100 ml at 37 C. The assay mixture contained an aliquot of mCatK (e.g. from the autoactivation assay) and 20 mM Cbz-Gly-Pro-Arg-AMC in 0.1 M sodium acetate pH 5.5 containing 2.5 mM DTT, 0.15 M NaCl, 0.1% PEG 6000, and 1 mM EDTA. The kinetics of the product release were continuously monitored in an Infinite M1000 microplate reader (Tecan) at excitation and emission wavelengths of 360 and 465 nm, respectively. The Michaelis-Menten kinetic parameters were determined by measuring the rate of hydrolysis of the substrate (0-100 lM) using the same assay with mCatK (0.4 nM); the K m value obtained by nonlinear regression using GraFit software was 17.4 mM.

Inhibition measurements were performed analogously. mCatK (0.42 nM) was added to a mixture of the fluorogenic substrate Cbz-Gly-Pro-Arg-AMC (20 mM) and an inhibitor (0-100 nM) in 0.1 M sodium acetate pH 5.5 containing 2.5 mM DTT, 0.15 M NaCl, 0.1% PEG 6000, and 1 mM EDTA. The substrate hydrolysis was monitored for 40 min. For the slow-binding inhibitor G€ u1303, an observed first-order rate constant k obs was calculated at each inhibitor concentration by fitting the progress curve to the equation P ¼ v s t þ (v i -v s )(1 -exp(k obs t))/k obs þ d, where P is the product formation, v s is the steady-state velocity, t is the reaction time, v i is the initial velocity, and d is offset. The apparent inhibition constant K i 0 was determined by non-linear regression using equa-

. The true inhibition constants K i were calculated using the Cheng Prusoff equation

is the substrate concentration and K m is the Michaelis constant. The apparent second-order rate constant k on 0 was determined by fitting to the linear equation k obs ¼ k 0 on [I] þ k off , and the true constant k on was calculated by correction k on ¼ k on

The fast-binding inhibitor G€ u2602 showed linear progress curves, and the apparent inhibition constant K i 0 was determined by non-linear regression using the Morrison equation for tight binding inhibition 58 with GraphPad Prism software. The concentration of mCatK was determined by active site titration as described previously 59 with E-64 used as the titrant 60 . The final concentration of DMSO in the assay systems did not exceed 1.5%.

Imaging of cathepsin K in human bone osteosarcoma cells (U-2 OS) was done as described previously using the CatK activitybased probe 25 40 . U-2 OS cells were cultivated in McCoy's 5 A medium supplemented with 10% FBS, 2 mM glutamax (L-alanyl-Lglutamine), 100 units/ml penicillin, and 100 lg/ml streptomycin at 37 C in 5% CO 2 . Fifty thousand cells were seeded into a well of a 12-well plate and allowed to attach. After 24 h, 1 lM probe was added, and cells were incubated for 16 h. Cells were detached using 0.25% trypsin-EDTA solution ( Merck), collected by centrifugation (500 g for 5 min), washed with PBS, resuspended in 100 ll of loading buffer, and heated at 100 C for 10 min. The competitive labelling was performed after the preincubation of cells with 1 lM G€ u1303 or G€ u2602 for 3 h. The samples (30 ll) were separated on 4-12% Bis-Tris polyacrylamide gels (Thermo Fisher Scientific). The gels were visualised using a Typhoon RGB imager (GE Healthcare Life Sciences) with excitation at 635 nm and emission at 660 nm (long pass filter).

Functional properties of the azadipeptide nitrile inhibitor G€ u1303 30 and the 3-cyano-3-aza-b-amino acid inhibitor G€ u2602 39 were characterised using an in vitro kinetic assay with the mature form of recombinant human cathepsin K (mCatK) and the fluorogenic substrate Cbz-Gly-Pro-Arg-AMC. Subnanomolar values of the inhibition constant K i were determined: Notably, we found a K i of 0.91 nM for G€ u1303 and an almost two orders of magnitude lower K i of 0.013 nM for G€ u2602 (Table 1) . A detailed analysis of the kinetic behaviour showed non-linear progress curves that indicated time-dependent inhibition for G€ u1303 typical for slowbinding inhibitors (Figure 2(A) ). This allowed for the calculation of the second-order rate constant of inactivation k on of 527 Â 10 3 M À1 s À1 , thus demonstrating the extraordinary potency of G€ u1303 (Table 1 ). In contrast, linear progress curves were obtained for G€ u2602 that are characteristic of fast-binding inhibitors (Figure 2(B) ).

The mature enzyme mCatK is generated during the acidic autocatalytic processing of an inactive precursor, the cathepsin K zymogen (pCatK), and this activation process is associated with the proteolytic removal of the propeptide domain from pCatK [24] [25] [26] . We examined the effect of G€ u1303 and G€ u2602 on the autoactivation of recombinant pCatK induced by acidic pH using an in vitro assay with SDS-PAGE visualisation of the processing forms pCatK and mCatK (bands of ca 37 kDa and ca 24 kDa, respectively) ( Figure 3(A) ). Inhibitors were tested under conditions providing full conversion to mCatK and the cleaved propeptide (a band of ca 10 kDa). Both inhibitors substantially suppressed the autoactivation processing of pCatK that resulted in approximately a 10-15% conversion compared to uninhibited conditions. Also, both inhibitors were able to suppress the autodegradation of the generated mCatK observed under prolonged incubation (compare 0.5 and 4 h experiments, Figure 3 (A)).

Finally, we investigated the interaction of the inhibitors with CatK using a cell-based assay with the human osteosarcoma cell line U-2 OS, which has an enhanced expression level of CatK 62 . For CatK imaging, we used a fluorescent activity-based probe that binds specifically and irreversibly to the active site of CatK 40 . Competition of the probe and inhibitor was monitored by SDS-PAGE and in-gel fluorescence. As shown in Figure 3 (B), both reversible inhibitors G€ u1303 and G€ u2602 strongly diminished the mCatK labelling, demonstrating that these cyanohydrazides are cell-permeable compounds that effectively interact with the active form of CatK in the lysosomal/endosomal system.

In conclusion, the cyanohydrazide inhibitors were demonstrated to inhibit mCatK with subnanomolar potency and different binding kinetics, to suppress the generation of mCatK from its zymogen, and to effectively target active mCatK in the cell context.

Human mature cathepsin K (mCatK) and a zymogen-like activation intermediate of cathepsin K (iCatK) were crystallised in complexes with two cyanohydrazide inhibitors, the azadipeptide nitrile G€ u1303 and the 3-cyano-3-aza-b-amino acid G€ u2602 (Figures 4  and 5) . The crystal structures of mCatK complexes with G€ u1303 and G€ u2602 were determined by molecular replacement using the structure of uncomplexed mCatK as a template. Both complexes crystallised in the orthorhombic space group P2 1 2 1 2 with one molecule in the asymmetric unit (Table S1 ). The structure of the mCatK-G€ u1303 complex was refined using data to resolution 1.55 Å, and to 2.00 Å for mCatK-G€ u2602. The final crystallographic models contained mCatK residues Ala1 to Met215; additional Nterminal residues derived from the propeptide, Gly-Arg (98p-99p, propeptide numbering), were visible in the mCatK-G€ u1303 0.91 ± 0.04 527 ± 8 0.48 ± 0.03 a The inhibition parameters were measured using a kinetic activity assay with the fluorogenic peptide substrate Cbz-Gly-Pro-Arg-AMC at pH 5.5. b n.d.: not determined for linear progress curves. structure ( Figure 5) . A comparison of both mCatK complexes did not reveal any significant differences in protein structure (a backbone r.m.s.d. of 0.51 Å, a value within the range observed for different crystal structures of identical proteins).

iCatK was produced by limited autocatalytic processing of the zymogen pCatK at acidic pH. This resulted in fragmentation of the propeptide with cleavage sites identified after Glu4p, Ser83p, and Arg86p residues by Edman sequencing and mass spectrometry peptide mapping analysis ( Figure 5(A) ). The obtained iCatK comprised two non-covalently bound domains (chains), namely the residual propeptide domain (Glu5p to Ser83p) and the main domain (Ser87p to Met215), including the C-terminal part of the propeptide and mCatK. The structure of the iCatK-G€ u2602 complex was solved by a combination of molecular replacement for the main domain (see previous paragraph) and automated model building by fragment-fitting technique for the residual propeptide. The structure of the iCatK-G€ u1303 complex was solved by molecular replacement based on the iCatK-G€ u2602 structure. Both iCatK complexes crystallised in the tetragonal space group P4 3 2 1 2 containing one molecule in the asymmetric unit (Table S1 ). The zoomed-in view of the mCatK active site shows a superposition of the inhibitors bound to the S1 to S3 subsites (corresponding inhibitor positions P1 to P3 are indicated). mCatK is displayed in surface representation (grey); highlighted are the catalytic residues Cys25 (yellow) and His162 (pink). Inhibitors are shown in stick representation with carbon atoms in cyan for G€ u1303 and magenta for G€ u2602; heteroatoms have standard colour coding (O, red; N, blue; S, yellow). (D) Interaction of the inhibitors with active site residues of mCatK. Left panels: the hydrogen bond network formed between inhibitors and mCatK residues (dashed black lines). Inhibitors are coloured as in (C), and interacting enzyme residues are in grey; the side chain of the covalently linked catalytic cysteine residue Cys25 is depicted. Right panels: the surface representation of the mCatK active site shows enzyme residues (highlighted in orange) forming nonpolar interactions with the inhibitors (in stick representation); both inhibitors are in the same orientation. (data absent in the iCatK structure are derived from the intact zymogen pCatK; PDB entry: 1BY8). Propeptide residues present or absent in the final crystallographic models of iCatK are in green or grey, respectively, residues of the catalytic domain are in black. The triangles above the sequence line indicate the N-and C-termini of the residual propeptid domain of iCatK, the N-termini of iCatK and mCatK catalytic domains as determined by the Edman sequencing and mass spectrometry (see the inset legend). The green dots show two residues of the propeptid of iCatK that form contacts with G€ u2602. The position of the N-termini is indicated for pCatK and catalytic domains of iCatK/mCatK. (B) The zoomed-in view of the iCatK active site shows a superposition of G€ u1303 and G€ u2602 bound to the S1 to S3 subsites (corresponding inhibitor positions P1 to P3 are indicated). iCatK is displayed in surface representation, the catalytic domain is highlighted in grey, the residual propeptide domain in green, and the catalytic residues Cys25 and His162 in yellow and pink, respectively. Inhibitors are shown in stick representation with carbon atoms in cyan for G€ u1303 and magenta for G€ u2602; heteroatoms have a standard colour coding (O, red; N, blue; S, yellow). (C) Interaction of the inhibitors with the iCatK active site residues. Left panels: the hydrogen bond network formed between inhibitors and iCatK residues with the (dashed black lines). Inhibitors are coloured as in (B), and interacting enzyme residues are in grey; the side chain of the covalently linked catalytic cysteine residue Cys25 is depicted. Superimposed (black) are the same inhibitors from the structures of their complexes with mCatK ( Figure 4 ). Right panels: the surface representation of the iCatK active site shows enzyme residues forming nonpolar interactions (highlighted in orange) with the inhibitors (in stick representation); both inhibitors are in the same orientation. The propeptide domain residues are highlighted in green. The final crystallographic model of the iCatK-G€ u1303 complex contained propeptide residues Asp8p to Gln73p and main domain residues Pro2 to Met215. The model of the iCatK-G€ u2602 complex contained residues Asp8p to Lys74p and Arg99p to Met215. The structures were refined using data to resolution 1.90 Å for iCatK-G€ u1303 and 1.88 Å for iCatK-G€ u2602. A comparison of iCatK complexes did not reveal any significant differences in protein structure (a backbone r.m.s.d. of 0.28 Å).

The residual propeptide domain of iCatK is folded in a similar manner to the intact propeptide in the structure of the zymogen pCatK (PDB: 1BY8) and bound at the same position (a backbone r.m.s.d. of 0.81 and 0.48 Å for the propeptide domains and catalytic domains, respectively). However, we observed a slightly different orientation of the a2p helix in iCatK complexes, which is rotated by approximately 10 compared to pCatK. The propeptide segment that blocks the active site in pCatK (downstream of the a3p helix, Figure 5) is proteolytically removed or flexible in iCatK, and therefore the active site cleft of iCatK becomes accessible for inhibitors. However, the residual propeptide domain partially occludes the primed region of the active site, in particular the S1' subsite of iCatK is occupied.

3.3.1. Binding mode of the azadipeptide nitrile G€ u1303 to mature and zymogen-like cathepsin K The active site cleft of mCatK contains the catalytic triad residues Cys25, His162, and Asn182. G€ u1303 is bound in a substrate-like orientation, and its P1 to P3 residues occupy the S1 to S3 subsites of mCatK (Figure 4(A,C) ). The cyanohydrazide warhead reacts with the thiol group of the catalytic Cys25, forming a covalent isothiosemicarbazide adduct through the connection to the C-atom of the nitrile moiety (Figure 4(B) ). Azadipeptides such as G€ u1303 are atropochiral molecules due to the restricted rotation around the methylated N-N axis, and, in the unbound state, they preferentially adopt the E-configuration of the respective CO-NMe bond 63, 64 (Figure 4(B) ). However, a Z-configuration at the CO-NMe bond was observed in G€ u1303 bound to mCatK, suggesting an Eto Z-conformational change in G€ u1303 upon binding to the enzyme, most likely due to a "configurational selection" that we recently reported for an azadipeptide nitrile inhibitor of the protease SmCB1 32 .

Interactions between G€ u1303 and the mCatK active site are presented in Figure 4 (D) (for details see Table S2 ). The inhibitor forms a network of hydrogen bonds with the active site residues. The nitrogen atom of the imidate moiety, derived from the warhead nitrile group, is stabilised by two hydrogen bonds to the backbone amide of the catalytic Cys25 and the side chain amide of Gln19 (Figure 4(D) ). An analogous interaction pattern was observed for the warhead of an azadipeptide nitrile inhibitor reacted with the protease SmCB1 (PDB: 6YI7) 32 . The NH of Gly66 acts as a bifurcated hydrogen bond donor for the carbonyl oxygen of the P2 phenylalanine and the noncarbonyl carbamate oxygen in the P3 position of G€ u1303. An additional hydrogen bond is formed between the Gly66 oxygen and the carbamate NH of G€ u1303. A similar network of Gly66-mediated hydrogen bonds was also reported for a Boc-protected precursor of a reactive activity-based probe for mCatK (PDB: 7NXL) 40 . Nonpolar interactions of G€ u1303 with mCatK are depicted in Figure 4 (D). They are absent in the S1 subsite, although the warhead containing the P1 azaalanine residue forms a number of contacts (Supporting information Table S2 ). At the P2 position, the phenylalanine residue makes nonpolar interactions with Tyr67, Ala134, Leu160, Ala163, and Leu209. The P3 benzyloxycarbonyl capping group forms nonpolar interactions with Asp61 and Tyr67, and the phenyl moiety of this group is stabilised by a T-shaped p-p stacking interaction to the 4-hydroxyphenyl group of Tyr67.

The binding mode of G€ u1303 in the active site of iCatK is analogous to that in mCatK, and there is no interaction of the inhibitor with the residual propeptide domain that blocks a part of the primed region of the iCatK active site (Figure 5(B) ). High conformational similarity of the inhibitor is indicated by a r.m.s.d. of 0.19 Å, with a certain change in the position of the P3 carbonyl oxygen. Also, G€ u1303 forms the same network of hydrogen bonds and nonpolar interactions in the S1 to S3 subsites of iCatK and mCatK ( Figure 5(C) , Table S2 ). However, no p-p stacking interaction with Tyr67 residue was observed, due to a slightly different orientation of the benzyloxycarbonyl capping group of G€ u1303.

Binding mode of the 3-cyano-3-aza-b-amino acid G€ u2602 to mature and zymogen-like cathepsin K G€ u2602 binds to the active site of mCatK in a substrate-like orientation, and the major conformation of the inhibitor occupies the S1 and S2 subsites (Figure 4(A,C) ). The cyanohydrazide warhead positioned centrally in the inhibitor molecule forms a covalent isothiosemicarbazide adduct with a thiol group of the catalytic Cys25 (Figure 4(B) ). There is a shift in the inhibitor backbone when comparing G€ u2602 and G€ u1303 that might be the result of nitrogen methylation in the warhead (CO-NH vs. CO-NMe in G€ u2602 and G€ u1303, respectively) (Figure 4(C) ). The CO-NH bond of G€ u2602 adopts the Z-configuration, similar to what has been observed for the CO-NMe bond of the enzyme bound inhibitor G€ u1303.

The nitrogen atom of the imidate moiety of G€ u2602 is strongly stabilised by three hydrogen bonds to the backbone amide of the catalytic Cys25, carbonyl group of Gly23, and the side chain amide of Gln19 (Figure 4(D) ). In contrast to G€ u1303, there is no hydrogen bonding between G€ u2602 and the Gly66 residue. However, a new hydrogen bond is formed between the backbone oxygen of Asn161 and the amide NH of G€ u2602. Analysis of the inhibitor-mCatK complexes available in the PDB shows that peptidomimetic inhibitors of mCatK frequently establish hydrogen bonding with Asn161 as well as Gly66 as important interaction determinants. The P1 and P2 residues of G€ u2602 are located in the non-primed subsites of the mCatK active site as follows (Figure 4(A,C) ). The Nbenzyl-N-methylacetamide substructure at P1 occupies the S1 subsite, making contacts with Gly23, Gly64, and Gly65 residues. Its terminal benzyl moiety is oriented out of the S1 subsite and towards the S2 pocket. The P2 Boc-capping group resides in the S2 subsite of mCatK and makes nonpolar interactions with Tyr67, Leu160, and Ala163 (Figure 4(D) , Table S2 ).

In general, G€ u2602 binds to the S1 and S2 subsites of iCatK in a manner that is similar to what has been shown for the G€ u2602-mCatK complex, with a r.m.s.d. of 1.23 Å; this value is substantially increased compared to G€ u1303 in its complexes, with a r.m.s.d. of 0.19 Å (Figure 5(B) ). The major conformational change, however, is in the benzyl group of the P1 N-benzyl-N-methylacetamide substructure. It is rotated towards the residual propeptide domain of iCatK and forms new contacts with its Val72p and Gln73p residues ( Figure 5(A,B) , Table S2 ). The terminal Boc group accommodates the S2 pocket of iCatK analogously as in mCatK. The network of hydrogen bonds is identical, and the pattern of nonpolar interactions (Tyr67, Asn161, and Ala163 in iCatK) is similar for both G€ u2602 complexes ( Figure 5(C) ).

The crystallographic electron density maps used for modelling G€ u1303 and G€ u2602 in the active site of mCatK were of high quality except for a weak electron density signal of the benzyl group of G€ u2602 (Figure 6(A) ). This prompted us to analyse the B-factor distribution in both inhibitors. The B-factor values were generally in the low range, but increased values were only found for the P1 N-benzyl-N-methylacetamide part of G€ u2602, with the highest value for its benzyl group (Figure 6(A) ). An analogous Bfactor pattern was also observed for inhibitors in iCatK complexes ( Figure S1 ). This finding indicated an increased flexibility and dynamic disorder of the major crystallographic conformation of the benzyl group of G€ u2602, which is located in the non-primed part of the active site and oriented out of the S1 subsite ( Figure 5 (C)).

A detailed inspection of electron density maps in the active site of the mCatK-G€ u2602 complex provided a further weak electron density signal of poor quality in the primed region of the mCatK active site that can be assigned to G€ u2602. Based on this signal, we attempted to model an alternative conformation of the benzyl group of G€ u2602, which is oriented towards the S2' subsite as presented in Figure 6 (B) (see conformation Y). For this purpose, we employed molecular modelling to examine conformational space of the flexible N-benzyl-N-methylacetamide substructure of G€ u2602. The molecular dynamics/quenching (MD/Q) technique was utilised to generate accessible conformations of this segment in the active site, and semiempirical quantum mechanical optimisation yielded a set of conformations with two general orientations into the non-primed and primed areas (the orientations are marked X and Y, respectively, in Figure 6 (B)).

In conclusion, we demonstrated that G€ u2602 is more flexible in the enzyme active site in contrast to the rigid ligand G€ u1303. The former contains a highly flexible benzyl moiety that is capable of adopting to two different types of conformations that reside in the non-primed part or primed part of the active site.

Cathepsin K (CatK) is a target for the treatment of osteoporosis, arthritis, and bone metastasis, and its potent and selective inhibitors are being intensively pursued as chemotherapeutics 6, 7, 24 . In this study, we investigated peptidomimetic inhibitors with a cyanohydrazide warhead, a class of highly efficient inhibitors of CatK that have been recently discovered 30, 31, 39 , yet for which the interaction mechanism at the atomic level with CatK is unknown. For two representative cyanohydrazide compounds, G€ u1303 and G€ u2602, we present crystallographic analysis of the binding mode to mature enzyme mCatK and its zymogen-like activation intermediate iCatK, as well as functional analysis in vitro and in cells.

The crystal structures of the complexes of G€ u1303 or G€ u2602 with mCatK showed that the inhibitors are bound in a substratelike orientation, and their cyanohydrazide warhead reacted with a thiol group of the catalytic Cys25, forming a covalent isothiosemicarbazide adduct. The CO-NMe and CO-NH bond (in G€ u1303 and G€ u2602, respectively) of the warhead adopted a Z-configuration in the mCatK active site. This is in line with our recent analysis of another cyanohydrazide inhibitor (with the azadipeptide nitrile scaffold) in the active site of a cysteine protease 32 which also demonstrated that the warhead with the methylated N-N axis provides atropochirality, and the E-configuration of the unbound inhibitor is transformed to a Z-configuration upon binding 32 . Therefore, such an E-to Z-conformational change in the course of its interaction with CatK is proposed for G€ u1303, containing the CO-NMe-NMe portion.

The cyanohydrazide warhead is differently positioned in the inhibitor scaffold of the azadipeptide nitrile G€ u1303 and 3-cyano-3-aza-b-amino acid G€ u2602. This is reflected in the distribution of the binding subsites that are targeted by the inhibitors. G€ u1303 occupies the non-primed subsites S1 to S3, and B-factor distribution showed that G€ u1303 is rigid in the mCatK active site. In contrast, G€ u2602 primarily occupies the S2 subsite, and the N-benzyl-N-methylacetamide part (especially its benzyl moiety) is highly flexible and has two alternative types of conformations that reside in the non-primed part (the S1 subsite) or primed part (the S2' subsite) of the active site. The non-primed orientation is the major one observed in the crystal structure, where it might be stabilised by additional contacts, including crystal packing contacts (with a symmetry-related protein molecule) and intramolecular contacts. The primed orientation was clearly demonstrated by molecular modelling using MD/Q and SQM techniques and is further supported by the recent identification of a benzyl group oriented towards the S2' pocket in the activity-based probe for CatK 40 . The computational approach showed a set of conformations for both types of orientations, further highlighting the high flexibility of this part of G€ u2602 in the enzyme active site. We hypothesise that the conformational flexibility of the complexed ligand at the boundary of the non-primed and primed subsites provides an entropic advantage contributing to the extraordinary potency of G€ u2602 in the low picomolar range. It has been shown that the loss of configurational entropy upon ligand binding contributes significantly unfavourably to the binding free energy 65 ; this entropy loss is decreased for G€ u2602 making its binding more favourable. An analysis of active site interactions formed by G€ u2602 also identified an important role of hydrogen bonding between the amide NH of the warhead and Asn161 of the S2 subsite, an interaction that is absent in G€ u1303. This is supported by analogues of G€ u2602 with methylated NH that exhibited a dramatic decrease in inhibitory potency by 3 orders of magnitude 39, 40 .

The differences in the binding mode between G€ u2602 and G€ u1303 are also reflected in their kinetic behaviour. The slowbinding of G€ u1303 is attributed to a conversion from an E-to Zconfiguration upon binding that was recently described as the kinetic controlling step for a prototype azadipeptide nitrile with an atropochiral warhead 32 . In contrast, the 3-cyano-3-aza-b-amino acid scaffold of G€ u2602 bears a non-atropochiral warhead, as demonstrated by NMR studies showing the absence of diastereotopic methylene protons 39 . Hence, the configuration conversion step does not occur, as is reflected by the fast-binding of G€ u2602 that resembles analogous kinetics and a reaction mechanism described for carbanitrile inhibitors 32 .

In addition to mCatK-inhibitor complexes, we also structurally characterised the complexes of G€ u2602 and G€ u1303 with the activation intermediate iCatK produced during autocatalytic processing of the inactive zymogen to mature enzyme that is associated with the removal of the propeptide. The iCatK structure is described here for the first time. It contains the main catalytic domain, which is non-covalently bound to the residual propeptide domain. Unlike the zymogen structure 27,28 , the residual propeptide (residues 4p to 83p) of iCatK only partially occluded the active site cleft (mainly the S1' subsite), and thus the catalytic centre is accessible for ligands. This contrasts to the previously investigated activation intermediate of the cathepsin SmCB1, in which the catalytic centre is still blocked by the residual propeptide 41 .

iCatK was demonstrated to bind G€ u2602 and G€ u1303 in an analogous manner to that observed in the mCatK complexes. This indicated that the iCatK active site is competent to bind inhibitory ligands in the available subsites and can be regulated by them. This conclusion is supported by the results on testing G€ u2602 and G€ u1303 in an in vitro autoactivation assay with the zymogen pCatK. It showed that both inhibitors strongly suppress the formation of mCatK from the zymogen that proceeds as a bimolecular processing reaction catalysed by functional forms of iCatK/mCatK. Furthermore, we provided evidence that G€ u2602 and G€ u1303 are capable of effectively targeting mCatK as well as the mCatK-generating pathway in the pathophysiologically relevant context of osteosarcoma cells.

In conclusion, our work provides the first crystallographic, computational chemical, and functional insights into the binding mode of the cyanohydrazide inhibitors to the CatK target and will facilitate a further rational design of therapeutics against CatKmediated pathologies.

Osteoporosis: mechanism, molecular target and current status on drug development

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

Novel therapies for osteoporosis

The future of cysteine cathepsins in disease management

Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned

Cathepsin K inhibitors for osteoporosis and potential off-target effects

Advances in the discovery of cathepsin K inhibitors on bone resorption

Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage

Br€ omme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics

Structural basis of collagen fiber degradation by cathepsin K

Cathepsin K: a unique collagenolytic cysteine peptidase

Conformational flexibility and allosteric regulation of cathepsin K

Structure-activity analysis of cathepsin K/chondroitin 4-sulfate interactions

Complexity of cancer protease biology: cathepsin K expression and function in cancer progression

Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response

Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia

Macrophage cathepsin K promotes prostate tumor progression in bone

IL-1alpha stimulates cathepsin K expression in osteoclasts via the tyrosine kinase-NF-kappaB pathway

Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis

CD133þ and Nestin þ glioma stem-like cells reside around CD31þ arterioles in niches that express SDF-1a, CXCR4, osteopontin and cathepsin K

Cathepsin K: a novel diagnostic and predictive biomarker for renal tumors

Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma

Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review)

Biochemical properties and regulation of cathepsin K activity

Autocatalytic activation of human cathepsin K

Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex

Crystal structure of wild-type human procathepsin K

The crystal structure of human procathepsin K

Chondroitin sulfate promotes activation of cathepsin K

Azadipeptide nitriles: highly potent and proteolytically stable inhibitors of papain-like cysteine proteases

Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors

Azanitrile inhibitors of the SmCB1 protease target are lethal to Schistosoma mansoni: structural and mechanistic insights into chemotype reactivity

Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents

Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors

Azapeptide synthesis methods for expanding side-chain diversity for biomedical applications

Azapeptides and their therapeutic potential

Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases

Specificity of aza-peptide electrophile activity-based probes of caspases

3-Cyano-3-azab-amino acid derivatives as inhibitors of human cysteine cathepsins

An activity-based probe for cathepsin K imaging with excellent potency and selectivity

Activation route of the Schistosoma mansoni cathepsin B1 drug target: structural map with a glycosaminoglycan switch

Mapping the pro-peptide of the Schistosoma mansoni cathepsin B1 drug target: modulation of inhibition by heparin and design of mimetic inhibitors

The macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: Current status and perspectives

An approach to multi-copy search in molecular replacement

Overview of the CCP4 suite and current developments

The Buccaneer software for automated model building. 1. Tracing protein chains

AceDRG: a stereochemical description generator for ligands

MolProbity: all-atom contacts and structure validation for proteins and nucleic acids

PLIP: fully automated protein-ligand interaction profiler

AMBER 14

Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements

Advanced corrections of hydrogen bonding and dispersion for semiempirical quantum mechanical methods

Cosmo -a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient

Reparametrization of the COSMO solvent model for semiempirical methods PM6 and PM7

Cuby: an integrative framework for computational chemistry

Optimization of parameters for semiempirical methods IV: extension of MNDO, AM1, and PM3 to more main group elements

High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants

Hemoglobin digestion in blood-feeding ticks: mapping a multipeptidase pathway by functional proteomics

L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L

The slow-binding inhibition of cathepsin K by its propeptide

Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis

Ottersbach PA, Schnakenburg G, G€ utschow M. Atropisomerism in azadipeptides: evaluation of N1-methylation and thioamide introduction

Ligand configurational entropy and protein binding

The authors thank Helena Mertl ıkov a-Kaiserov a for providing U-2 OS cells. Diffraction data were collected on MX14.1 at the BESSY II electron storage ring operated by the Helmholtz-Zentrum Berlin.

No potential conflict of interest was reported by the authors.

This work was supported by the project ChemBioDrug CZ.02.1.01/ 0.0/0.0/16_019/0000729 from ERDF/OPRDE and the institutional project RVO 61388963.

Atomic coordinates and experimental structure factors have been deposited in the Protein Data Bank with accession codes 7QBL, 7QBM, 7QBN, and 7QBO.